NCT06957808View on ClinicalTrials.gov

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Schizophrenia Disorders
Interventions
DRUG

Diroximel fumarate (DRF)

Diroximel fumarate is an immunomodulating drug licensed for use in multiple sclerosis. It has been found to cross the blood brain barrier and increase brain glutathione levels.

DRUG

Placebo

A placebo pill given to participants.

Trial Locations (3)

SE58AZ

RECRUITING

South London and Maudsley NHS Foundation Trust, London

WC1E 6BT

RECRUITING

Department of Computer Science, Faculty of Engineering Science, University College London, London

B15 2TT

RECRUITING

School of Psychology, University of birmingham, Birmingham

All Listed Sponsors
collaborator

Rosetrees Trust

OTHER

lead

King's College London

OTHER